Back to today’s briefing

Story perspectives

EMA Approves AI Tool to Revolutionize NASH Treatment Trials

3/20/2025

32 3

Summary

Story summary

The EMA's CHMP has granted its inaugural Qualification Opinion for AIM-NASH, an innovative AI tool that evaluates liver biopsy scans to determine MASH severity. By minimizing variability in disease activity assessments, this groundbreaking method promises to streamline clinical trials and accelerate the development of effective MASH treatments for patients across Europe.

1 of 1

Story summary

The EMA's CHMP has granted its inaugural Qualification Opinion for AIM-NASH, an innovative AI tool that evaluates liver biopsy scans to determine MASH severity. By minimizing variability in disease activity assessments, this groundbreaking method promises to streamline clinical trials and accelerate the development of effective MASH treatments for patients across Europe.